Mirtazapine in L-dopa-induced dyskinesias

Clinical Neuropharmacology

Volumn 26, Issue 4, 2003, Pages 179-181

  Meco, Giuseppe ^a,b   Fabrizio, Edito ^a   Di Rezze, Simone ^a   Alessandri, Andrea ^a   Pratesi, Luca ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Department of Neurological Sciences ^*  (Italy)

Author keywords

Dyskinesias; Mirtazapine; Parkinson disease

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; AMANTADINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BUSPIRONE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; MIRTAZAPINE; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE; SEROTONIN 1A AGONIST; SEROTONIN 2 ANTAGONIST; TANDOSPIRONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG ANTAGONISM; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG SAFETY; DYSKINESIA; FEMALE; HUMAN; MALE; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; RETICULAR FORMATION; SUBSTANTIA NIGRA;

AGED; AMANTADINE; ANALYSIS OF VARIANCE; DRUG THERAPY, COMBINATION; DYSKINESIA, DRUG-INDUCED; HUMANS; LEVODOPA; MIANSERIN; MIDDLE AGED; STATISTICS, NONPARAMETRIC;

EID: 0042134789     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-200307000-00005     Document Type: Article

References (9)

1. Gorman JM. Mirtazapine: clinical overview. J Clin Psychiatry. 1999;(suppl 17)60:9-13.
2. Screiber S, Rigai T, Katz Y, et al. The antinociceptive effect of mirtazapine in mice is mediated through serotoninergic, noradrenergic and opioid mechanisms. Brain Res Bull. 2002;58:601-605.
3. Bonifati V, Fabrizio E, Cipriani R, et al. Buspirone in levodopa-induced dyskinesias. Clin Neuropharmacol. 1994;17:73-82.
4. Kannari K, Kurahashi K, Tomiyama M, et al. Tandospirone citrate, a selective 5-HT1A agonist, alleviates L-dopa-induced dyskinesia patients with Parkinson's disease. No To Shinkei. 2002;54:133-137.
5. Fox SH, Brotchie JM. 5-HT2c receptor binding is increased in the substantia nigra pars reticulata in Parkinson's disease. Mov Disord. 2000;15:1064-1069.
6. Meco G, Marini S, Lestingi L, et al. Controlled single-blind crossover study of ritanserin and placebo in L-dopa-induced dyskinesias in Parkinson's disease. Current Ther Res. 1988;43:262-270.
7. Rascol O, Arnulf I, Peyro-Saint Paul H, et al. Idazoxan, an alpha-2 antagonist and L-dopa induced dyskinesias in patients with Parkinson's disease. Mov Disord. 2001;16:708-713.
8. Verhagen ML, Del Dotto P, van den Munckhof P, et al. Amantadine as treatment for dyskinesias and motor fluctuation in Parkinson's disease. Neurology. 1998;50:1323-1326.
9. Pact V, Giduz T. Mirtazapine treats resting tremor, essential tremor and L-dopa-induced dyskinesias. Neurology. 1999;53:1154.